Stallergenes Greer Earns 2026 Switzerland’s Best Managed Companies Award for Excellence in Leadership, Innovation, and Sustainable Growth
Stallergenes Greer, a global leader in allergy immunotherapy and allergy care, has been honored with the prestigious 2026 Switzerland’s Best Managed Companies Award, recognizing the company’s outstanding business performance, strategic leadership, operational excellence, and long-term commitment to innovation and sustainable growth.
The award places Stallergenes Greer among an elite group of privately held Swiss companies that have demonstrated exceptional management practices across multiple aspects of business operations. The recognition highlights the company’s ability to consistently execute its long-term strategy while fostering a strong corporate culture, maintaining financial discipline, investing in innovation, and creating sustainable value for patients, employees, healthcare professionals, and other stakeholders.
For Stallergenes Greer, the achievement represents another important milestone in its more than 120-year history of advancing allergy care through scientific innovation and patient-focused healthcare solutions.
Recognition Through an Internationally Respected Program
The Switzerland’s Best Managed Companies Award is part of Deloitte’s internationally recognized Best Managed Companies program, which has become one of the world’s leading benchmarks for evaluating privately owned businesses.
The global initiative has been developed over more than three decades and is currently implemented in more than 50 countries, recognizing organizations that demonstrate excellence in business management and corporate leadership.
Companies participating in the program undergo a comprehensive and highly competitive evaluation process conducted by an independent panel of experts.
Rather than focusing solely on financial performance, the assessment examines multiple dimensions of organizational excellence, including strategic planning, innovation, operational effectiveness, corporate governance, company culture, employee engagement, leadership capabilities, and long-term financial sustainability.
Only organizations demonstrating consistently high performance across all these categories are selected for recognition.
A Reflection of Long-Term Strategic Execution
According to Stallergenes Greer, the award reflects years of disciplined execution of its corporate strategy while continuing to expand its global presence in the allergy care market.
The company has steadily strengthened its position through investments in research and development, manufacturing capabilities, industrial operations, and international market expansion.
These investments have enabled Stallergenes Greer to continue delivering allergy immunotherapy solutions while responding to the evolving needs of physicians and patients around the world.
At the same time, the company has maintained a strong emphasis on operational excellence, ensuring that growth is supported by sound financial management, effective governance, and efficient execution.
The award recognizes the company’s ability to balance innovation with operational discipline, allowing it to pursue sustainable expansion without compromising quality or organizational stability.
Commitment to Scientific Innovation
Innovation continues to play a central role in Stallergenes Greer’s long-term strategy.
As one of the world’s established companies specializing in allergy diagnosis and immunotherapy, the organization continues investing in scientific research aimed at improving treatment options for individuals living with allergic diseases.
Its research programs focus on developing therapies designed to modify the underlying causes of allergic reactions rather than simply managing symptoms.
The company believes that continuous scientific advancement is essential to improving patient outcomes while addressing the increasing global prevalence of allergic diseases.
Investments in research infrastructure, manufacturing technologies, and product development have become important pillars supporting Stallergenes Greer’s future growth strategy.
Expanding Global Presence
Another factor contributing to the company’s recognition is its expanding international footprint.
Over recent years, Stallergenes Greer has continued strengthening its presence across multiple healthcare markets, bringing its allergy care solutions to an increasing number of patients worldwide.
This international expansion has required careful coordination across research, manufacturing, regulatory affairs, supply chain management, and commercial operations.
Successfully managing these complex activities while maintaining consistent quality standards has contributed to the company’s reputation as a well-managed global healthcare organization.
The Best Managed Companies evaluation recognized the company’s ability to align international growth with operational resilience and strategic clarity.
A Culture Built Around Patients and Employees
Beyond financial and operational achievements, the award also recognizes the importance of organizational culture.
Stallergenes Greer attributes much of its success to a workplace culture centered on scientific excellence, collaboration, agility, and patient-focused decision-making.
The company seeks to create an environment where employees are encouraged to contribute innovative ideas while maintaining the high standards required within the healthcare industry.
This emphasis on people extends beyond internal operations to include relationships with healthcare professionals, research partners, and patients.
According to the company, maintaining a patient-centered approach remains fundamental to every aspect of its business, from product development through commercial execution.
The award acknowledges how this culture supports both organizational performance and long-term sustainability.
Leadership Highlights the Contribution of Employees
Dr. Andreas Amrein, Chairman of the Board and Chief Executive Officer of Stallergenes Greer, emphasized that the recognition belongs to the company’s employees, whose daily commitment has helped transform strategic objectives into measurable achievements.
He noted that every member of the organization contributes to the company’s success by embracing its values, maintaining high standards of execution, and fostering a culture that combines operational rigor with organizational agility.
According to Dr. Amrein, disciplined management has remained one of the defining characteristics of Stallergenes Greer throughout its long history.
He explained that the company has consistently pursued excellence while remaining committed to advancing allergy care through scientific innovation and responsible business leadership.
Receiving the Switzerland’s Best Managed Companies Award, he said, serves as both recognition of past accomplishments and motivation to continue raising standards for patients, healthcare professionals, and employees around the world.
Dr. Amrein also suggested that international recognition strengthens the company’s ability to attract talented professionals who share its commitment to innovation and improving patient care.
Excellence Across Multiple Business Dimensions
The Best Managed Companies evaluation identified several areas where Stallergenes Greer demonstrated exceptional performance.
Among the company’s recognized strengths were its clear strategic vision, agile leadership structure, operational resilience, innovation-driven growth strategy, and robust corporate governance framework.
Together, these characteristics create a strong foundation for sustainable long-term value creation.
Rather than relying solely on financial success, the program evaluates how effectively organizations integrate strategy, innovation, employee engagement, governance, and operational excellence into a cohesive management approach.
Stallergenes Greer’s recognition reflects consistent performance across each of these critical areas.
Independent Evaluation Process
One of the distinguishing features of the Best Managed Companies program is its rigorous and independent evaluation methodology.
Participating organizations undergo an extensive review conducted by experienced business leaders and industry experts.
The Swiss edition of the program draws upon more than thirty years of global best practices developed through Deloitte’s international Best Managed Companies initiative.
The evaluation framework is designed to identify organizations that demonstrate not only strong current performance but also the leadership capabilities and governance structures necessary for long-term success.
This comprehensive approach makes the award particularly meaningful within the international business community.
Broad Industry Collaboration
The Switzerland’s Best Managed Companies program is organized by Deloitte Private in collaboration with several prominent Swiss institutions, including SIX Swiss Exchange, the Zurich Chamber of Commerce, EFG Private Banking, and WillisHenry.
These organizations collectively support the initiative by recognizing companies that demonstrate exemplary business leadership while contributing to Switzerland’s reputation as a global center for innovation and economic excellence.
The collaborative nature of the program further reinforces the credibility of the recognition awarded to participating companies.
Deloitte Recognizes Outstanding Business Leadership
Commenting on this year’s award recipients, Andreas Bodenmann, Best Managed Companies Program Leader at Deloitte Switzerland, congratulated the winning organizations for successfully completing an intensive evaluation process.
He noted that the recognized companies demonstrated exemplary management practices across the four principal pillars of the program: strategy, productivity and innovation, culture and commitment, and governance and financial management.
According to Bodenmann, companies receiving the distinction have proven their ability to manage their organizations at an exceptionally high standard while maintaining sustainable business practices capable of supporting continued long-term growth.
Continuing to Advance Allergy Care
For Stallergenes Greer, receiving the 2026 Switzerland’s Best Managed Companies Award represents more than external recognition of business performance. It reflects the company’s broader mission of improving the lives of individuals living with allergies through scientific innovation, responsible leadership, and operational excellence.
As allergic diseases continue to affect millions of people worldwide, the company remains focused on expanding access to effective allergy immunotherapy solutions while investing in research, industrial capabilities, and talent development. By combining a clear strategic vision with strong governance, financial discipline, and a patient-centered culture, Stallergenes Greer aims to continue strengthening its position as a global leader in allergy care.
The award serves as recognition of the company’s achievements to date while reinforcing its commitment to delivering sustainable growth, advancing medical innovation, and creating lasting value for patients, healthcare professionals, employees, and stakeholders across the global healthcare community.
About Switzerland’s Best Managed Companies
Switzerland’s Best Managed Companies program is an awards program recognizing privately held companies for their organizational success and achievement. The program provides a distinct framework for management teams to challenge themselves and benchmark against some of the best private companies in the world.
The Best Managed Companies program was established in 1993 in Canada and has become the most significant business award of its kind. The program is active in 50+ countries across the Americas, Europe and Australasia.
For more information on the awards program, visit: www.bestmanagedcompanies.ch
About Stallergenes Greer
Headquartered in Baar (Switzerland), Stallergenes Greer is a leading global biopharmaceutical company specializing in allergy immunotherapy for human and veterinary use. Its activities span the full value chain, from product development and commercialization to allergy diagnosis and treatment. Backed by more than 120 years of expertise and innovation, the company’s products reach patients in 46 countries worldwide.
